Response to comment on: Perioperative probiotics or synbiotics in adults undergoing

elective abdominal surgery: a systematic review and meta-analysis of randomized controlled

trials

Abeed H Chowdhury, PhD, FRCS¹, Alfred Adiamah, MRCS¹, Anisa Kushairi, BMedSci, BM BS¹,

Dileep N Lobo, DM, FRCS, FACS, FRCPE^{1, 2}

¹Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK

²MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK

Key words: elective abdominal surgery; meta-analysis; outcomes; probiotics; synbiotics

Word count: (excluding title page and references) 560

Declaration of interests: A.H.C., A.A. and A.K. have no conflicts of interest to declare. D.N.L. has received an unrestricted research grant for unrelated work from BBraun in the last 3 years. He has also received speakers' honoraria from BBraun, Fresenius Kabi, Shire, and Baxter Healthcare for unrelated work in the last 3 years.

Corresponding author

Professor Dileep N Lobo Gastrointestinal Surgery Nottingham University Hospitals Queen's Medical Centre Nottingham NG7 2UH UK Tel: +44-115-8231149 Fax: +44-115-8231160 Email: <u>Dileep.Lobo@nottingham.ac.uk</u> ±

Reply

We thank Wu et al, for their interest in our systematic review and meta-analysis¹ and for their comments.

Our primary end point was postoperative infectious complications, and to achieve this aim, we ensured that studies met the criterion of reporting infectious complications. Indeed, if the primary aim of using probiotics or synbiotics is to reduce infectious complications, then any study that failed to report this fundamental outcome was not deemed appropriate for inclusion. Based on the Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (section 3.2.4.1), the measurement of certain outcomes in a study may be an eligibility criterion; especially when the review addresses the potential for an intervention (probiotics or synbiotics) to prevent a particular outcome (infectious complications).² In accordance with this rationale, studies that used the intervention (probiotics or synbiotics) for purposes other than preventing infectious complications and, therefore, did not record infectious complications were ineligible.

Moreover, Berman and Parker³ recommended that meta-analyses should address only one or two primary outcomes to focus the analytic process. It is unlikely that all studies relating to secondary outcomes would be obtained from the initial electronic search as they were not the initial purpose of our analysis.¹ Therefore, a completely different protocol and search strategy would be required to perform a rigorous meta-analysis on secondary outcomes such as length of stay and mortality. This was beyond the scope of our metaanalysis.¹

We restricted our inclusion criteria to patients undergoing abdominal surgery in an effort to maintain sufficient clinical homogeneity in terms of population to provide a meaningful

2

summary. We argue that patients undergoing surgery for congenital heart disease are sufficiently different from patients undergoing liver transplantation to the point of introducing significant clinical heterogeneity. That, however, does not suggest that probiotics are of no benefit in extra-abdominal surgical procedures.

In the trial sequential analysis (TSA) performed by Wu et al. on our meta-analysis¹ the cumulative Z-curve crossed both the conventional boundary and the trial sequential monitoring boundary for benefit. That is supportive of our conclusion that the use of the probiotics led to significant reduction in infectious complications.

However, it is important to stress that different probiotics and synbiotics differ significantly in their effects on the gut microbiome and that it would be inappropriate to extrapolate the beneficial effect of one strain or combined preparation to another. Therefore, a TSA confirming the efficacy of probiotics or synbiotics taken in isolation could inadvertently be misinterpreted. It was for this reason we were cautious not to include a TSA, as it would have highlighted benefits of "all probiotics" without the caveat that this benefit is limited to only the strains utilised in the studies included in this meta-analysis.¹

There is a fundamental issue in several levels of subgroup analysis in the absence of enough studies as all it does is reduce power and reintroduces selection bias. The Cochrane Handbook acknowledges the usefulness of subgroup analyses in investigating heterogeneity, but stipulates that findings from multiple subgroup analyses may be misleading.⁴ The observational nature of subgroup analyses (as opposed to randomised comparisons) increases the risk of false negatives and false positives.⁵ Due to the potential errors that can be introduced by subgroup analyses, we opted to be careful regarding splitting participant information into separate analyses.

3

Our meta-analysis strengthens the confidence in the overall benefit of probiotics and

synbiotics in patients undergoing abdominal surgery.

References

1 Chowdhury AH, Adiamah A, Kushairi A, et al. Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. *Ann Surg* 2019 [Epub ahead of print] doi: 10.1097/SLA.00000000003581.

2 McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.

3 Berman NG, Parker RA. Meta-analysis: Neither quick nor easy. *BMC Med Res Methodol* 2002;2:10.

4 Deeks JJ Higgins JPT, Altman DG; on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.

5 Borenstein M, Higgins JPT. Meta-analysis and subgroups. *Prev Sci* 2013;14:134-143.